Annan Scandinavian College of Neuropsychopharmacology årliga kongressen
2023-06-09 16:00 Add to iCal
Välkommen att delta på Scandinavian College of Neuropsychopharmacology (SCNP) årliga kongress. Dagarna är fyllda med information om den senaste forskningen.
Registrering
Registrering görs via SCNP hemsida, https://scnp.org. Anmälningsavgift: 3495 DKK.
I avgiften ingår tillgång till alla pass, fika och luncher. Medlemmar i SCNP får en rabatt på DKK 500. Du kan ansöka om medlemskap på hemsidan.
Plats och logi
Mötet kommer att äga rum i Biomedicum vid Karolinska Institutet, Stockholm, Sverige.
Se mer information på hemsidan, där även boende kan bokas.
Utvalda ämnen och talare
Future therapies for Alzheimer’s disease
Lars Lannfelt, Uppsala University (Sweden)
Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder
Susanne Bejerot, Örebro University (Sweden)
Cannabis — The Good, The Bad and the Ugly in Relation to Psychiatric Disorders
Yasmin Hurd, Icahn School of Medicine at Mount Sinai (USA)
Treatment Strategies for ADHD and Co-occurring Substance Use/Use Disorders
Frances Levin, Columbia University (USA)
Psychedelics in depression – opportunities and challenges
Ole Andreassen, Oslo (Norway)
Targeting Brain Kynurenic Acid for Cognitive Improvement
Robert Schwarcz, University of Maryland (USA)
Suicide prevention- how to turn the tide?
Merete Nordentoft, University of Copenhagen (Denmark)
Management of treatment-resistant depression: old ideas (& new)
Elias Eriksson, Gothenburg University (Sweden)
SCNP Young Scientist Symposium (SCNP Award)
Speakers selected based on competition
Du hittar det mer detaljerade programmet här.
Om SCNP
SCNP was founded in Copenhagen in 1959, and has since been a major player in research, innovation and education related to medical psychiatric treatment in the Nordic countries: Denmark, Sweden, Norway, Iceland and Finland. Many notable observations and studies has been carried out by the SCNP and its members, e.g. the discovery and development of the first SSRI antidepressants. Today SCNP and its journal, 'Acta Neuropsychiatrica' , continues these proud traditions.